UroGen Pharma (URGN) Misses Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- S&P Global explores potential separation of Capital IQ business
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- Clear Street Starts Forgent Power Solutions (FPS) at Buy
UroGen Pharma (URGN) PT Lowered to $36 at Raymond James
March 11, 2025 9:47 AM EDTRaymond James analyst Reni Benjamin lowered the price target on UroGen Pharma (NASDAQ: URGN) to $36.00 (from $40.00) while maintaining a Outperform rating.
The analyst comments "4Q Jelmyto sales of $24.6M were a bit below $25.6M consensus estimate. We should soon... More



